Tag: Prescription Drugs
Rebound of COVID-19 Symptoms Rare After Nirmatrelvir/Ritonavir Treatment
Only 0.8 percent of 483 patients with mild-to-moderate SARS-CoV-2 at high risk for severe disease progression had rebound
Atogepant Prevents Migraine in Adults
Compared with placebo, increase in responder rates seen at all atogepant dose levels
Cost of Brand-Name Antiseizure Meds Increased Since 2010
Brand-name ASMs accounted for 79 percent of costs in 2018, despite representing only 14 percent of pill days
ENDO: Fezolinetant Cuts Vasomotor Symptoms in Menopause
Frequency and severity of vasomotor symptoms reduced with fezolinetant versus placebo through 12 weeks
New ALS Drug Approved in Canada While Still Under FDA Review
Last month, 38 U.S. doctors who treat ALS patients sent a letter urging the FDA to approve the drug
RAAS Inhibitors May Cut Risk for Rupture in Brain Aneurysm
Rupture risk reduced compared to non-RAAS antihypertensive drugs even among patients with controlled hypertension
ASCO: Ramucirumab Plus Pembrolizumab Promising in NSCLC
In phase 2 trial, overall survival longer with combo treatment compared with investigator's choice for standard of care in advanced NSCLC
New Drug Launch Prices Increasing Exponentially Each Year
Findings among newly marketed brand-name prescription drugs launched in 2008 to 2021
ASCO: Desmoplastic Melanoma Responds to Neoadjuvant Pembrolizumab
Fifty-six percent of patients had pathologic complete response after neoadjuvant treatment with pembrolizumab
More Clinical Benefits of Molnupiravir ID’d in COVID-19
Compared with placebo, normalization of C-reactive protein and oxygen saturation faster, with improvements seen on day 3 of treatment
